908. Outcomes Research: Myeloid Malignancies: Poster II

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) – a Chart Review Study in the United States

Factors Associated with Quality of Life Impairments in Patients with Myeloproliferative Neoplasms: Looking Beyond Symptom Burden

Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Burden and Clinical Outcomes in Patients (pts) with Myelofibrosis (MF) and Anemia Treated with Ruxolitinib (RUX): Data from the Veterans Affairs Corporate Data Warehouse (VACDW)

Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial

Inequalities in Treatment Utilization Among Older Medicare Beneficiaries with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Induction Therapy

Ponatinib Safety Profile: An Analysis of 10 Years of Real-World Experience

Pattern and Outcomes of Synchronous Neoplasms in Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasm (MPN): A SEER Database Analysis

Disseminated Intravascular Coagulation and Early Thrombo-Hemorrhagic Complications in Acute Promyelocytic Leukemia

FDA Analysis of Race and Ethnic Enrollment of Clinical Trials for Drug Registration in Adult Patients for Leukemia and Myelodysplastic Syndrome

Real-World Treatment Patterns and Blood Count Control in Patients with Polycythemia Vera Who Switched from Hydroxyurea to Ruxolitinib

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

Genetic Profiling and Risk Stratification of Acute Myeloid Leukemia (AML): Comparative Analysis of the Jordanian AML Cohort (JAMLC) to the German-Austrian AML Study Group (AMLSG)

Experienced or Perceived Burdens and Associated Quality of Life Impacts of Anemia and Transfusion Dependence in Myelofibrosis: A Patient Self-Report Survey Analysis

Developments in Therapeutics and Impact on AML Survival in Older Patients: A Populational Analysis

Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Associations between Myeloid Malignancies and Osteoporosis Using Real-World Data from the Trinetx Database

Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR)

Retrospective Evaluation of BCR::ABL Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World Experience

Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings